Skip to main content
construction release_alert
Profile editing will be unavailable for Scholars@Duke profiles from June 11-24, 2026 as manual profile data entry transitions to Elements. More information about the transition.
cancel

Donald Benjamin Sanders

Professor Emeritus of Neurology
Neurology, Neuromuscular Disease
Duke Box 3403, Durham, NC 27710
1255 Hosp South, Durham, NC 27710

Overview


Research Interests:
1. Therapy of neuromuscular disease - immunologic and neuromuscular facilitating agents for myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS).
2. Clinical trials in nerve, muscle and neuromuscular diseases

Current Appointments & Affiliations


Professor Emeritus of Neurology · 2025 - Present Neurology, Neuromuscular Disease, Neurology

In the News


Published December 23, 2015
Patients fear spike in price of old drugs

View All News

Recent Publications


The Duke MG Patient Registry III. Comparative Effectiveness of Azathioprine and Mycophenolate Mofetil in Generalized Myasthenia Gravis, a Retrospective Single Center Review.

Conference Muscle Nerve · May 2026 INTRODUCTION/AIMS: Azathioprine (AZA) and mycophenolate mofetil (MMF) are the most commonly used non-steroidal immunosuppressants in patients with generalized myasthenia gravis (gMG) in North America but their relative effectiveness among disease subgroups ... Full text Link to item Cite

Immunotherapies in autoimmune neuromuscular junction disorders: Acute and chronic management.

Journal Article Handb Clin Neurol · 2026 Myasthenia gravis (MG) is the most common disease of the neuromuscular junction. Conventional immunotherapy based on corticosteroids and immunosuppressants has been in use for several decades and has greatly contributed to the improvement of the disease pr ... Full text Link to item Cite

Sensitivity of Repetitive Nerve Stimulation Performed in Early and Later Stages of Myasthenia Gravis.

Journal Article Muscle Nerve · October 2025 INTRODUCTION/AIMS: Repetitive nerve stimulation (RNS) is a valuable tool in the diagnostic evaluation of myasthenia gravis (MG). However, there are conflicting reports of its sensitivity when performed ≤ 30 days from symptom onset. We aim to compare the se ... Full text Link to item Cite
View All Publications

Recent Grants


Defining the clinical phenotype and immunopathology of seronegative MG

ResearchKey Faculty · Awarded by Myasthenia Gravis Foundation · 2021 - 2023

Prospective Multicenter Observational Cohort Study of Comparative Effectiveness of Disease-Modifying Treatments for Myasthenia Gravis (MG)

Clinical TrialPrincipal Investigator · Awarded by Patient-Centered Outcomes Research Institute · 2017 - 2022

Real World Outcomes of Surgical and Medical Management in Myasthenia Gravis

ResearchMentor · Awarded by American Academy of Neurology · 2019 - 2022

View All Grants

Education


Harvard University · 1964 M.D.